Scientists from St. Jude Children's Research Hospital have shown that the innate immune sensor, ZBP1, and its associated inflammatory cell death pathway, PANoptosis, are major contributors to the ...

SAN FRANCISCO -- A company hoping to market an inhalable formulation of interferon beta for viral lung diseases isn't dissuaded by phase III trial results in 623 hospitalized COVID-19 patients, which ...

In a recent study published in The New England Journal of Medicine, researchers used the TOGETHER platform trial protocol to perform a phase III randomized controlled trial (RCT) to evaluate the ...

Present interferon-based therapy for chronic hepatitis C is limited by both efficacy and tolerability. Telaprevir and boceprevir are the first two direct-acting antiviral drugs (DAAs) that inhibit ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A single dose of pegylated interferon lambda used as ...

In 1980, TIME Magazine wrote about interferon as the “if” drug for cancer. Promising studies sparked widespread hope around the potential of the interferon to treat cancer, only if it could deliver ...

Early interferon therapy reduces secondary myelofibrosis risk in young ET and PV patients. Cytoreductive drugs do not lower thrombotic event risk in young patients. Elevated white blood cell counts ...

Northwestern Medicine investigators have discovered a novel signaling pathway activated by interferons, a group of immune system proteins, that suppresses the anti-tumor response of interferons in ...

Antiviral treatment with intravesical interferon provides better pain reduction in women with interstitial cystitis over 6 months compared with intravesical hyaluronic acid. Women with interstitial ...

NEW YORK (Reuters Health) - Early treatment of multiple sclerosis (MS) patients with interferon beta-1b therapy may help slow down the onset of disability, according to a report in this week's issue ...

A new retrospective study of patients with high-risk t(8;21) acute myeloid leukemia (AML) investigated outcomes from 2 therapies following return of minimal residual disease–positive status after ...